Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD

NCT06828887 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

MDD

Interventions

DRUG: LV232 40mg
DRUG: LV232 60mg
DRUG: Escitalopram
DRUG: Placebo

Sponsor

Vigonvita Life Sciences